Please amend claims 1-16 to read as follows:

- 1. Amended

 1. Ame
- 2. The mammal according to claim 1, wherein the oncogene is controlled by the WAP promoter.
- 3. The mammal according to claim 1, wherein the oncogene is a gene coding for SV40 T-Aq.
- 4. The mammal according to claim 1, wherein the sequence codes for the n118 epitope of the LCM virus nucleoprotein having the amino acid sequence of SEQ ID NO: 2.
- 5. The mammal according to claim 3, wherein the mammal is selected from the group consisting of WAO-T-NP6, WAP-T-NP8 and WAP-T-NP10.
- 6. "The mammal according to claim 1 with inducible ductal carcinoma in situ (DCIS), wherein the mammal contains an oncogene that can be activated by lactotropic hormones and is selected from the group consisting of WAP-T-1, WAP-T-2 and WAP-T-10.
- 7. "The mammal according to claim 1, wherein DCIS develops into an invasive ductal mammary carcinoma.

- 8. The mammal according to claim 1, wherein the lactotropic hormones are estrogen, prolactin, insulin, and hydrocortisone.
- 9. A method of providing a mammal that contains an oncogene that can be activated by lactotropic hormones, comprising the steps of:
 - (a) introducing a DNA coding for an oncogene into inseminated oocytes of a mammal, the DNA code being SEQ ID NO: 1 and being controlled by a promoter specific to lactotropic horomones,
 - (b) implanting the oocytes from (a) into pseudopregnant mammals, and
 - (c) selecting the progeny obtained in (b) for the formation of DCIS.

Contr

- 10. The method according to claim 9, wherein the promoter is the WAP promoter.
- 11. The method according to claim 9, wherein the oncogene is a gene coding for SV40 T-Ag.
- 12. The method according to claim 9, wherein the sequence codes for the n118 epitope of the LCM virus nucleoprotein having the amino acid sequence of SEQ ID NO: 2.
- 13. The method according to claim 12, wherein the lactotropic hormones comprise estrogen, prolactin, insulin and hydrocortisone.
- 14. The method according to claim 9, wherein DCIS develops

4121-127

into invasive ductal mammary carcinoma.

15. Use of the mammal according to claim 1 for studying DCIS, its progression towards an invasive ductal carcinoma and the latter.

C)

16. Use of the mammal according to claim 1 for the research and development of diagnostic markers and therapeutic agents for a DCIS or an invasive ductal carcinoma.